EATONTOWN, NJ / ACCESSWIRE / February 25, 2021 / American CryoStem Corporation (OTC PINK: CRYO), a clinical-stage biotechnology company, global licensor and pioneer in autologous cell therapy and therapies, today announced that it has entered into an agreement with BioTherapeutic Labs Corp. (BTL) an umbilical cord registered by the FDA Tissue Manufacturing Company headquartered in Boca Raton, Florida.
CRYO will optimize umbilical cord cell recovery to deliver umbilical cord cells under its previously announced “CRADA” agreement with the Biomedical Research Laboratory in Bethesda, Maryland, and for future IND applications. The agreement includes the commercialization by BTL of CRYO’s products and services, as well as collaborative R&D efforts related to the development and improvement of protocols using both CRYO’s ATCell® autologous mesenchymal stem cells and human umbilical cord product lines from BTL. The companies plan to validate and standardize the cell-free umbilical cord suspension product for use with its ATCell ™ manufacturing, product development and end-to-end CryoStem platform technology.
The Company is confident that this collaboration will enable the creation of advanced regenerative therapeutics to further enhance CRYO and BTL’s mission as biologics manufacturers and cell developers and produce therapies of great value to the medical and research communities, and finally, the general public. Our translational research will support treatment protocols and applications for approval using mesenchymal stem cells derived from adipose tissue and / or products derived from the umbilical cord. Management believes that these new products can be commercialized to generate substantial sales and licensing revenues and create value for the Company’s stakeholders.
John Arnone, CEO, said: “Our collaboration ultimately aims to facilitate the creation of new cell processing therapies to be used independently or in tandem with CRYO’s current ATCell.® autologous products to improve the level of care of patients suffering from diseases with limited or no treatment options. ” [unmet medical needs]. Mr. Arnone added: “The objective is to improve the modulation of the immune response (s) and to promote tissue regeneration and stability (homeostasis) for the treatment of traumatic injuries, inflammation, autoimmune diseases. -immunes and brain and organ damage associated with new viruses such as SARS-CoV-2 (COVID-19).
Sandy Lipkins, CEO of Biotherapeutic Labs Corp. said, “This collaboration allows us to offer both adipose tissue and umbilical cord products and therapies to physicians and their patients through our national sales network. Our network of sales representatives and physicians is thrilled to have access to one of the first autologous adipose tissue cell solutions available. We will engage with CRYO in collaborative R&D efforts to test new products and develop new advanced therapies. It is truly an honor to work with CRYO and we believe that our collaboration will yield incredible results. “
About BioTherapeutic Labs Corp.
BioTherapeutic Labs Corp (BTL), is an FDA registered life sciences company dedicated to the research, development, manufacture and distribution of anti-aging, aesthetic, musculoskeletal, wound care and of advanced hair loss treatment. BTL is committed to advancing products and therapies using human biologics to their full potential. BTL manufactures its products in a cGMP compliant facility, specializing in the production of mesenchymal stem cells derived from adipose tissue and umbilical cord derived products for regenerative therapy. The Company’s proprietary aseptic processing techniques produce products free of endotoxins and microorganisms, while maintaining the structural integrity of the tissue. BTL sells its products through a nationwide network of licensed distributors, agents and healthcare professionals. www.biotherapeuticlabs.com
About American CryoStem
American CryoStem Corporation (OTC PINK: CRYO), is a clinical-stage biotechnology company, a global licensor and a pioneer in autologous cell therapy and therapies. The Company’s Centralized Lab Model and Patented Foundational “CryoStem Platform” is a premier end-to-end cell therapy solution for treating chronic injuries, disorders and diseases through a single harvest of adipose tissue (fat) and ATCELL Bank ™ cryopreservation. The Company creates personalized therapies based on mesenchymal stem cells derived from adipose tissue and offers successive multiple treatments of genetically adapted cells as needed. American CryoStem is dedicated to helping physicians, hospitals and clinics around the world improve clinical outcomes by developing and delivering effective cutting-edge stem cell therapies that improve the health and quality of life of patients. The Company has an FDA registered cGMP compliant laboratory located in Monmouth Junction, New Jersey. The Company’s proprietary end-to-end centralized laboratory fat tissue processing platform consists of “Collection – Processing – Cryobank – Return to Point of Care” – On Demand, Fat Tissue and Mesenchymal Stem Cells derived from adipose.
THE SOURCE: American company CryoStem
See the source version on accesswire.com: